Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer: An exploratory subgroup analysis of a global, randomized, phase 3 clinical trial

Journal of Thoracic Oncology

Volumn 7, Issue 3, 2012, Pages 567-573

  Belani, Chandra Prakash ^a   Wu, Yi Long ^b   Chen, Yuh Min ^c   Kim, Joo Hang ^d   Yang, Sung Hyun ^e   Zhang, Li ^f   Peterson, Patrick ^g   Orlando, Mauro ^h  

^a PENN STATE CANCER INSTITUTE   (United States)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d Yonsei University College of Medicine   (South Korea)

^e Korea Cancer Center Hospital   (South Korea)

^f SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^g ELI LILLY AND COMPANY   (United States)

^h Edificio Panamericana Plaza   (Argentina)

Author keywords

Carcinoma; East Asian; Maintenance therapy; Non small cell lung; Nonsquamous; Pemetrexed

Indexed keywords

PEMETREXED;

ACNE; ADULT; ADVANCED CANCER; ANOREXIA; ARTICLE; CANCER SURVIVAL; CARE AND CARING; CHINA; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTE; HUMAN; KOREA; LEUKOCYTE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEUTROPHIL; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TAIWAN; THROMBOCYTE;

EID: 84857910629     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31823d4f9d     Document Type: Article

References (13)

1. Baldwin CM, Perry CM. Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer. Drugs 2009;69:2279-2302.
2. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-263.
3. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
4. Data on file, Eli Lilly and Company, March 20, 2008.
5. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
6. Yang CH, Simms L, Park K, et al. Efficacy and safety of cisplatin/ pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial. J Thorac Oncol 2010;5:688-695.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
8. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, version 3.0. [National Cancer Institute, US National Institutes of Health Web Site]. August 9, 2006. Available at: http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed April 11, 2011.
9. Hirsch FR, Bunn PA Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009;10:432-433.
10. Jiang H. Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol 2009;39:137-150.
11. Ou SH, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009;4:1083-1093.
12. Lee HY, Ahn MJ, Park YH, et al. Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial. Lung Cancer 2009;66:338-343.
13. Maeda R, Yoshida J, Ishii G, et al. The prognostic impact of cigarette smoking on patients with non-small cell lung cancer. J Thorac Oncol 2011;6:735-742.